Introduction {#s1}
============

DNA methylation patterns are established by DNA methyltransferase enzymes (Dnmts), for which two categories have been defined based on in vitro assays. The 'de novo*'* methyltransferases, Dnmt3a and Dnm3b, establish novel patterns of DNA methylation, and prefer to bind unmethylated DNA in vitro ([@bib30]). The 'maintenance' methyltransferase, Dnmt1, has a high affinity for hemi-methylated DNA in vitro, and preserves DNA methylation in replicating cells ([@bib2]; [@bib24]). Dnmts are crucial for embryonic development in mice, as mice null for *Dnmt1* or *Dnmt3b* arrest at mid-gestation, and *Dnmt3a* null mice die in the first few weeks of life ([@bib25]; [@bib31]). Although DNA methylation is not necessary for murine embryonic stem (ES) cell growth, the differentiation of *Dnmt1*-hypomorphic and *Dnmt3a; Dnmt3b*-mutant ES cells is severely impaired ([@bib6]; [@bib17]; [@bib23]; [@bib35]). These results indicate an important role for DNA methylation and Dnmts in directing cell differentiation processes.

One of the primary consequences of hypomethylation is increased DNA damage and genomic instability. Global hypomethylation in mice results in chromosome duplications and invasive T-cell lymphomas at four months of age ([@bib13]), and in mouse ES cells, loss of *Dnmt1* also causes global hypomethylation and increased mutation rates ([@bib5]). In the HCT116 colorectal cancer cell line, ablation of the catalytically active DNMT1 results in cell cycle arrest and apoptosis due to increased chromosomal instability ([@bib7]; [@bib34]). In mouse embryonic fibroblasts, ablation of either *Dnmt1* ([@bib18]) or *Dnmt3b* ([@bib8]) causes gradual hypomethylation, deregulated gene expression, and cell death. Dnmt1 and DNA methylation are also required for viability in most proliferating somatic cell populations, including human skin cells ([@bib32]), mouse embryonic fibroblasts ([@bib18]), and neuronal ([@bib12]) and pancreatic ([@bib14]) progenitor cells.

Interestingly, Dnmt1 is not required for adult intestinal stem cell survival ([@bib33]). The mature intestinal epithelium is a single cell layer lining the lumen of the intestine, structured into finger-like protrusions, designated 'villi', and invaginations into the underlying mesenchymal tissue, termed 'crypts.' Intestinal stem cells are located in the crypt and respond to multiple signaling pathways that control proliferation and differentiation ([@bib10]). Stem cells give rise to rapidly dividing transit-amplifying cells, which move in ordered cohorts up the crypt-villus axis. As cells migrate out the crypt, they differentiate into one of several distinct cell lineages, a process that is largely dependent on levels of Notch signaling. Loss of Dnmt1 in the adult mouse intestinal epithelium causes hypomethylation of regulatory regions associated with several intestinal stem cell genes, resulting in inappropriate gene expression during differentiation, and expansion of the crypt zone ([@bib33]). In contrast, ablation of *Dnmt1* during intestinal crypt development causes hypomethylation, DNA damage, and apoptosis of epithelial cells, resulting in increased perinatal lethality ([@bib11]). Previous studies did not investigate the requirement for Dnmt1 in maintaining global DNA methylation or preserving genomic stability in the mature intestine. Thus, the mechanism behind preservation of the *Dnmt1*-mutant adult intestinal epithelium, the only rapidly dividing somatic tissue known to survive without Dnmt1, is not known.

To determine the mechanism underlying *Dnmt1* mutant intestinal survival, we employed tissue-specific, inducible mouse models and analyzed the effects immediately after *Dnmt1* deletion in the adult intestinal epithelium. Ablation of *Dnmt1* caused an acute phenotype characterized by weight loss, global DNA hypomethylation, genome instability, and apoptosis. Strikingly, animals returned to baseline DNA methylation levels within two months of *Dnmt1* deletion, indicating recovery by a de novo methyltransferase. We demonstrate that the de novo methyltransferase Dnmt3b is upregulated following loss of Dnmt1, and essential for epithelial survival in the Dnmt1 mutant intestine. Our results implicate a role for DNA methylation, maintained by both Dnmt1 and Dnmt3b, in protecting genomic stability in intestinal epithelial homeostasis. These data are the first to show that Dnmt3b can function in maintenance DNA methylation in vivo.

Results {#s2}
=======

*Dnmt1* ablation results causes weight loss, hypomethylation, and genomic instability {#s2-1}
-------------------------------------------------------------------------------------

To determine the primary effects of Dnmt1 deletion in the adult intestinal epithelium, we employed an inducible, intestinal epithelial-specific gene ablation model. The *Dnmt1^loxP/loxP^;Villin-CreERT2* mice (Dnmt1 mutants) and their *Dnmt1^loxP/loxP ^*siblings (controls) were tamoxifen-treated at four weeks of age to induce Cre recombinase activity ([@bib9]; [@bib18]). Although Dnmt1 mutants lost a significant amount of weight in the two weeks following Cre induction, mice recovered by day 17 post-tamoxifen treatment, and survived at rates identical to controls ([Figure 1A--B](#fig1){ref-type="fig"}). To elucidate the mechanism underlying acute weight loss, we isolated Dnmt1 mutant and control intestines one week following tamoxifen treatment.10.7554/eLife.12975.003Figure 1.*Dnmt1* ablation results in genomic instability and apoptosis one week following tamoxifen treatment.(**A**, **B**) *Dnmt1^loxP/loxP^*(control, n=5) and *Dnmt1^loxP/loxP^;Villin-CreERT2* (Dnmt1 mutant, n=9) mice were tamoxifen treated at four weeks of age, and weighed every day over a 17-day period. Dnmt1 mutants lost a significant amount of weight by day 11, but recovered to near-starting weight by day 16. \*p\<0.05, Student's *t*-test. (**B**) All *Dnmt1* mutants survive the 17-day time-course described in (**A**), similar to controls. (**C--D**) Hematoxylin and Eosin staining of control and Dnmt1 mutant intestines. One week post-ablation, Dnmt1 mutants exhibit loss of crypt integrity, vacuolization of the epithelium, and an increase in crypt fission (**D**) compared to controls (**C**). (**E--F**) Immunohistochemistry confirms loss of Dnmt1 protein in mutants one week following tamoxifen treatment (**F**) relative to control intestine (**E**). (**G**-**H**) Immunofluorescent staining for Ki67 (red), which marks proliferating cells, and γH2AX (green), which marks DNA double-strand breaks as a marker of chromosomal instability. One week following Dnmt1 ablation, mutant crypts display increased levels of γH2AX foci (**H**, yellow arrows) relative to controls (**G**). Dnmt1 mutants also display slightly enlarged crypts (Ki67 in **H** versus **G**), as described previously ([@bib33]). (**I--J**) Immunofluorescent TUNEL staining (red), which marks apoptotic nuclei, and E-cadherin (green), to outline the intestinal epithelium. One week after tamoxifen treatment, Dnmt1 mutants display increased crypt cell apoptosis (**J**, yellow arrows) compared to controls (**I**). (**K--L**) Crypts were isolated from paraffin-embedded tissue by laser capture microdissection, and the methylation levels of *LINE1* loci and the imprinting control region of *H19* were determined by targeted bisulfite sequencing. One week after tamoxifen treatment, methylation of LINE1 (**K**) and *H19* (**L**) are significantly decreased in Dnmt1 mutants compared to controls (n=4 per genotype). \*\*\*p\<0.001, \*p\<0.05, Student's *t*-test. For data and *p* values, refer to [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}. Error bars represent S.E.M. Scale bars are 50 μm. For all staining, n=3 biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.003](10.7554/eLife.12975.003)10.7554/eLife.12975.004Figure 1---source data 1.Contains mouse weight/survival data in [Figure 1A--B](#fig1){ref-type="fig"}, targeted bisulfite sequencing data in [Figure 1K--L](#fig1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.004](10.7554/eLife.12975.004)

One-week post-tamoxifen treatment, Dnmt1 mutants exhibited multiple abnormalities in intestinal epithelial morphology, with partial loss of epithelial integrity and a high frequency of crypt fission ([Figure 1C--D](#fig1){ref-type="fig"}). Dnmt1 loss was confirmed on the protein level by immunohistochemistry ([Figure 1E--F](#fig1){ref-type="fig"}), and the Dnmt1 mutant epithelium displayed a slight expansion of the proliferative crypt zone ([Figure 1G--H](#fig1){ref-type="fig"}), as reported previously ([@bib33]). However, Dnmt1 mutant epithelia also exhibited regions that lacked crypts and/or villi, juxtaposed with hyperplastic crypts that replaced damaged tissue ([Figure 1D](#fig1){ref-type="fig"}). Since Dnmt1 ablation results in increased double stranded breaks and apoptosis in the neonatal intestine ([@bib10]), we investigated if the Dnmt1 deficient adult intestine also displayed altered genomic stability. As a general marker of chromosomal instability, we stained for γH2AX, which labels DNA double strand break foci, and is an indicator of the DNA damage response. We observed an increase in γH2AX foci in the crypts of Dnmt1 mutants compared to controls, which displayed minimal DNA double strand breaks ([Figure 1G--H](#fig1){ref-type="fig"}). We also performed TUNEL staining to identify apoptotic nuclei, and found that the Dnmt1 mutant intestine exhibited increased crypt cell apoptosis relative to the control intestinal epithelium, which did not contain any apoptotic nuclei ([Figure 1I--J](#fig1){ref-type="fig"}).

To determine global DNA methylation levels, we isolated mutant and control intestinal crypt epithelium by laser capture microdissection, and performed targeted bisulfite-sequencing of the repetitive *LINE1* loci. *LINE1* retrotransposons account for approximately 20% of the mouse genome ([@bib38]), and are a representative of genome-wide DNA methylation levels ([@bib22]; [@bib40]). The *LINE1* repeats were significantly demethylated in Dnmt1 mutant crypts, with methylation reduced to approximately 50% of controls at each CpG analyzed ([Figure 1K](#fig1){ref-type="fig"}). We also performed bisulfite sequencing of the *H19* imprinting control region to analyze maintenance methylation, and found that the region was slightly demethylated relative to controls, although this difference was only significant when comparing the methylation of the entire sequenced region ([Figure 1L](#fig1){ref-type="fig"}). Overall, these results suggest a phenotype in which loss of Dnmt1 results in hypomethylation of LINE1 repeats and the H19 imprinting control region, increased DNA damage, and apoptosis.

Dnmt1-deficient intestinal epithelium recovers within two months of tamoxifen treatment {#s2-2}
---------------------------------------------------------------------------------------

Interestingly, *Dnmt1^loxP/loxP^;Villin-CreERT2* mutant mice survive at rates comparable to controls ([Figure 1B](#fig1){ref-type="fig"}), indicating that Dnmt1 is not required for continued intestinal maintenance in the adult mouse. To determine the long-term effects of *Dnmt1* ablation, we harvested Dnmt1 mutant and sibling control intestines two months following tamoxifen injection. We confirmed that Dnmt1 deletion had been maintained in mutant epithelia ([Figure 2C--D](#fig2){ref-type="fig"}), but found that Dnmt1 mutant intestinal epithelial morphology ([Figure 1A--B](#fig1){ref-type="fig"}) and proliferation ([Figure 1E--F](#fig1){ref-type="fig"}) were comparable to controls. In addition, levels of DNA damage and apoptosis, as indicated by γH2AX and TUNEL staining, respectively, were similar to control mice ([Figure 2E--H](#fig2){ref-type="fig"}). We isolated crypt cells from two-month Dnmt1 mutants and controls by laser-capture microdissection, and performed targeted bisulfite sequencing for *LINE1* and *H19*, as described above. LINE1 methylation levels remained significantly decreased compared to controls ([Figure 2I](#fig2){ref-type="fig"}), but demethylation was not as severe compared to Dnmt1 mutants at one-week post-tamoxifen treatment (compare [Figure 2I](#fig2){ref-type="fig"} to 1K). Strikingly, methylation at the *H19* imprinting control region had been fully restored ([Figure 2J](#fig2){ref-type="fig"}). These results implicate a mechanism that compensates for loss of Dnmt1 and leads to recovery of intestinal epithelial DNA methylation and genomic integrity.10.7554/eLife.12975.005Figure 2.The Dnmt1 mutant intestinal epithelium recovers with time.*Dnmt1^loxP/loxP^*(control) and *Dnmt1^loxP/loxP^;Villin-CreERT2* (Dnmt1 mutant) mice were tamoxifen treated at four weeks of age, and intestines were harvested two months later for immunostaining and DNA methylation analysis. (**A--B**) Hematoxylin and eosin staining revealed that two months following tamoxifen treatment, the Dnmt1 deficient epithelium appears similar to controls (**B** versus **A**). (**C--D**) Epithelial Dnmt1 deletion is maintained in Dnmt1 mutants two months after tamoxifen injections (**D** versus **C**). (**E--F**) Immunofluorescent staining for Ki67 (red), which marks proliferating cells, and γH2AX (green), which marks DNA double-strand breaks as a marker of chromosomal instability. By two months post-Dnmt1 deletion, the mutant epithelium has returned to baseline levels of DNA damage (**F** versus E control). (**G--H**) TUNEL staining (red), which marks apoptotic nuclei, and immunostaining for E-cadherin (green), to outline the intestinal epithelium. Two months following tamoxifen injection, Dnmt1 mutants appear similar to controls and display no apoptosis in the epithelium (**H** versus **G**, respectively). (**I**,**J**) Crypts were isolated from paraffin-embedded tissue by laser capture microdissection, and the methylation levels of *LINE1* loci and the imprinting control region of *H19* were determined by targeted bisulfite sequencing. Two months following tamoxifen injection, Dnmt1 mutants have mostly regained methylation at both the LINE1 (**E**) and *H19* (**F**) loci, and are comparable to controls (n=5--6 per genotype). However, the slight demethylation across the entire LINE1 loci is significantly decreased compared to controls. For data and *p* values per CpG, refer to [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}. Error bars represent S.E.M. Scale bars are 50 μm. For all staining, n=3 biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.005](10.7554/eLife.12975.005)10.7554/eLife.12975.006Figure 2---source data 1.Contains targeted bisulfite sequencing data presented in [Figure 2I--J](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.006](10.7554/eLife.12975.006)

The de novo methyltransferase Dnm3b, but not Dnmt3a, is upregulated following Dnmt1 deletion {#s2-3}
--------------------------------------------------------------------------------------------

We surmised that the de novo methyltransferases might compensate for loss of Dnmt1, and performed qRT-PCR and immunofluorescent staining for both Dnmt3a and Dnmt3b in mutant and control intestines harvested one week following tamoxifen treatment. We confirmed loss of *Dnmt1* mRNA in mutant crypts by qRT-PCR, but observed no changes in *Dnmt3a* transcript or protein expression ([Figure 3A--C](#fig3){ref-type="fig"}). In addition, simultaneous loss of both Dnmt1 and Dnmt3a did not alter or exaggerate the Dnmt1 mutant phenotype, or result in decreased viability ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). *Dnmt1^loxP/loxP^;Dnmt3a^loxP/loxP^;Villin-CreERT2* mice (Dnmt1;Dnmt3a mutants) displayed acute changes in cell death, and *LINE1* and *H19* methylation, identical to those seen in *Dnmt1* mutants ([Figure 3---figure supplements 1G-H](#fig3s1){ref-type="fig"} and [2A--B](#fig3s2){ref-type="fig"}). Furthermore, *Dnmt1;Dnmt3a* mutants do not exhibit increased γH2AX foci compared to single Dnmt1 deficient mice ([Figure 3---figure supplement 1E--F](#fig3s1){ref-type="fig"}). Combined with its unchanged protein and mRNA expression, we concluded that Dnmt3a is not required for the recovery of *Dnmt1* mutant epithelia.10.7554/eLife.12975.007Figure 3.*Dnmt3b* is upregulated following *Dnmt1* ablation.*Dnmt1^loxP/loxP^*(control) and *Dnmt1^loxP/loxP^;Villin-CreERT2* (Dnmt1 mutant) intestines were harvested one week following tamoxifen treatment for gene expression and immunostaining analysis. (**A**) qRT-PCR comparing the relative gene expression levels of Dnmt1, Dnmt3a, and Dnmt3b in the jejunum of tamoxifen-treated controls and Dnmt1 mutants (n=3--4 per genotype). Compared to controls, Dnmt1 mutants express significantly lower levels of Dnmt1, while Dnmt3b expression is significantly increased. Gene expression was calculated relative to the geometric mean of TBP and β-actin. p\<0.01, Student's *t*-test. For data and *p*-values, refer to [Figure 3---source data 1](#SD3-data){ref-type="supplementary-material"}. (**B--C**) Controls (**B**) and Dnmt1 mutants (**C**) display similar levels of Dnmt3a protein (green). (**D--E**) Dnmt1 mutants (**E**) display elevated Dnmt3b protein in intestinal crypts, compared to controls (**E**). Error bars represent S.E.M. Scale bars are 50 μm. For all staining, n=3 biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.007](10.7554/eLife.12975.007)10.7554/eLife.12975.008Figure 3---source data 1.Contains qPCR data and analysis shown in [Figure 3A](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.008](10.7554/eLife.12975.008)10.7554/eLife.12975.009Figure 3---source data 2.Contains targeted bisulfite sequencing data presented in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.009](10.7554/eLife.12975.009)10.7554/eLife.12975.010Figure 3---figure supplement 1.Deletion of *Dnmt3a* in addition to *Dnmt1* causes no additive effects on epithelial proliferation, genome stability or cell death within one week.(**A**,**B**) Dnmt1^loxP/loxP^; Dnmt3a^loxP/loxP^ (**A**, control) and *Dnmt1^loxP/loxP^;Dnmt3a^loxP/loxP^;Villin-CreERT2* (B, Dnmt1;Dnmt3a mutant) intestinal epithelium one week after tamoxifen injection. Immunohistochemistry for Dnmt1 confirms loss of protein in tamoxifen-treated Dnmt1;Dnmt3a mutant relative to controls. (**C**,**D**) Immunofluoresence for Dnmt3a confirms loss of protein in tamoxifen-treated Dnmt1;Dnmt3a mutant intestinal epithelium (**D**) compared to control (**C**). (**E**,**F**) Co-staining for Ki67 (red), a marker of proliferation, and γH2AX (green), which marks DNA double-stranded breaks. Control (**E**) has minimal γH2AX foci. Dnmt1;Dnmt3a mutants (**F**) have increased proliferation, similar to what is seen in Dnmt1 mutants. Contrary to Dnmt1 deletion, Dnmt1;Dnmt3a mutants do not display increased γH2AX foci one week after tamoxifen injection. (**G**,**H**) TUNEL staining to detect apoptosis (red) with E-cadherin (green) to outline the epithelium. Controls (**G**) display no apoptotic nuclei in crypt cells. Dnmt1;Dnmt3a mutants (**H**) display a slight increase in apoptosis, similar to what is observed in Dnmt1 mutant crypts one week after tamoxifen injection. All scale bars are 50 μm. For all staining, n=3 biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.010](10.7554/eLife.12975.010)10.7554/eLife.12975.011Figure 3---figure supplement 2.Ablation of *Dnmt3a* and *Dnmt1* induces genome demethylation at *LINE1* and *H19* loci.Intestines from *Dnmt1^loxP/loxP^;Dnmt3a^loxP/loxP^*(control, n=2) and *Dnmt1^loxP/loxP^;Dnmt3a^loxP/loxP^;VilllinCreERT2* (Dnmt1;Dnmt3a mutant, n=3) mice were harvested one week after tamoxifen treatment. Crypt cells were isolated by laser capture microdissection and the methylation levels of *LINE1* loci and the imprinting control region of *H19* were determined by targeted bisulfite sequencing. (**A**,**B**) Methylation of LINE1 (**A**) and *H19* (**B**) are significantly decreased in Dnmt1;Dnmt3a mutants one week after tamoxifen treatment. In all graphs, error bars are S.E.M. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, Student's *t*-test. For data and p-values per CpG, refer to [Figure 3---source data 2](#SD4-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.011](10.7554/eLife.12975.011)

In contrast, *Dnmt3b* mRNA expression was significantly increased in the *Dnmt1* mutant crypts compared to control crypt cells ([Figure 3A](#fig3){ref-type="fig"}). In agreement with our qRT-PCR data, we discovered an increase in Dnmt3b protein levels in the mutant intestinal epithelium while expression levels in the lamina propria were unchanged ([Figure 3D--E](#fig3){ref-type="fig"}), suggesting that *Dnmt3b* is upregulated within one week of *Dnmt1* ablation. Overall, these data suggest a mechanism in which *Dnmt3b* is activated to counteract the loss of *Dnmt1* in the intestinal epithelium. We next aimed to test this proposed compensation mechanism using mouse genetics.

Dnmt3b is required for survival of intestinal epithelial-specific Dnmt1 mutant mice {#s2-4}
-----------------------------------------------------------------------------------

To directly test the requirement for *Dnmt3b* in maintaining DNA methylation in the *Dnmt1* mutant intestinal epithelium, we bred the *Dnmt3b^loxP/loxP^*allele onto the mutant genotype ([@bib28]), producing *Dnmt1^loxP/loxP^;Dnmt3b^loxP/loxP^;Villin-CreERT2*, along with *Dnmt1*^loxP/loxP^;*Dnmt3b*^loxP/loxP^ siblings as controls. To assess the overall requirement for *Dnmt3b* in *Dnmt1* mutant survival, we injected tamoxifen into groups of *Dnmt1*^loxP/loxP^;*Dnmt3b*^loxP/loxP^;Villin-Cre-ERT2 mutants (*Dnmt1;Dnmt3b* mutants) and littermate controls at four weeks of age, and weighed mice each day following CreERT2 induction. 60% of *Dnmt1;Dnmt3b* mutant mice (n=10) became severely morbid within two weeks following tamoxifen administration and had to be euthanized ([Figure 4A--C](#fig4){ref-type="fig"}). *Dnmt1;Dnmt3b* mutants lost significantly more weight compared to *Dnmt1* mutants, which contributed to the increased lethality observed in double mutant mice ([Figure 4B--C](#fig4){ref-type="fig"}). In contrast, 94% of *Dnmt1* mutant mice (n=16) survived to 17 days following tamoxifen injection, confirming that loss of *Dnmt1* alone is non-lethal in the mature intestinal epithelium ([Figure 4A](#fig4){ref-type="fig"}). *Dnmt1;Dnmt3b* mutant mice that survived contained intestinal epithelium positive for *Dnmt3b* ([Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}) resulting from inefficient Cre-mediated gene ablation followed by expansion of "escaper" crypts, consistent with our hypothesis that *Dnmt3b* is required to preserve epithelial integrity in the absence of *Dnmt1*.10.7554/eLife.12975.012Figure 4.Loss of both *Dnmt1* and *Dnmt3b* in the intestinal epithelium results in decreased survival.(**A**) Percent survival of *Dnmt1^loxP/loxP^;Dnmt3b^loxP/loxP^*(control, n=8), *Dnmt1^loxP/loxP^;Villin-CreERT2* (Dnmt1 mutant, n=16), and *Dnmt1^loxP/loxP^;Dnmt3b^loxP/loxP^;Villin-CreERT2*(Dnmt1;Dnmt3b mutant, n=10). All mice were tamoxifen treated at four weeks of age, and followed 17 days to record weight and survival. Significantly fewer Dnmt1;Dnmt3b mutants survive, compared to both controls and Dnmt1-deficient mice. \*\*\*p\<0.001, Log-rank test. (**B**) Percent of initial weight each day following tamoxifen treatment in (**A**). Gradual weight loss is observed in both Dnmt1 mutants (white diamonds) and Dnmt1;Dnmt3b mutants (grey triangles). (**C**) Statistical comparison of weight loss between controls, Dnmt1 mutants, and Dnmt1;Dnmt3b mutants. At day 10 post-tamoxifen treatment, both mutant groups have lost a significant amount of weight relative to controls. Dnmt3b;Dnmt1 mutants have also lost significantly more weight relative to Dnmt1 mutants. At day 15, both mutant genotypes weigh significantly less than controls. \*\*p\<0.01, \*\*\*p\<0.001, one-way ANOVA. For all data and p-values, refer to [Figure 4---source data 1](#SD5-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.012](10.7554/eLife.12975.012)10.7554/eLife.12975.013Figure 4---source data 1.Contains mouse weight and survival data analysis in [Figure 4](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.013](10.7554/eLife.12975.013)10.7554/eLife.12975.014Figure 4---figure supplement 1.*Dnmt1;Dnmt3b* mutant intestinal epithelia contain *Dnmt3b*^*+* ^escaper crypts, which do not display DNA damage.Intestines were harvested from mutant *Dnmt1^loxP/loxP^;Dnmt3b^loxP/loxP^;Villin-CreERT2* (Dnmt1;Dnmt3b mutant) and sibling *Dnmt1^loxP/loxP^;Dnmt3b^loxP/loxP^*controls one week post-tamoxifen treatment. Immunofluorescent staining was performed for Dnmt3b (red), γH2AX (green) to visualize DNA double strand breaks, and DAPI (blue) to stain nuclei. The majority of mutant crypts are null for Dnmt3b relative to control (yellow arrows in B pointing out Dnmt3b-null crypts). However, some mutants contain Dnmt3b-positive crypts, which escaped Cre-loxP recombination (white outline in B). The escaper crypts do not display elevated levels of DNA damage compared to the Dnmt3b-ablated epithelium (yellow arrow points out γH2AX staining in a Dnmt3b-null crypt). Scale bars are 50 μm. For all staining, n=3 biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.014](10.7554/eLife.12975.014)

Next, we isolated small intestines from *Dnmt1;Dnmt3b* mutants and sibling controls one week after tamoxifen administration for DNA methylation and immunostaining analysis. We employed laser-capture microdissection to isolate one-week *Dnmt1;Dnmt3b* mutant and control crypt cells for DNA methylation analysis. As expected, *Dnmt1;Dnmt3b* mutants were significantly demethylated at the LINE1 loci compared to controls ([Figure 5A](#fig5){ref-type="fig"}). Although the *Dnmt1;Dnmt3b* mutants displayed decreased methylation levels relative to Dnmt1 mutants, this difference was not statistically significant across the entire region ([Figure 5A](#fig5){ref-type="fig"}). The H19 imprinting control region was slightly demethylated in compared Dn*mt1;Dnmt3b* mutants to controls, but was only significant when comparing the entire sequenced region ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).10.7554/eLife.12975.015Figure 5.Simultaneous loss of *Dnmt1* and *Dnmt3b* results in acute genomic instability, increased apoptosis, and genome demethylation.(**A**) *Dnmt1^loxP/loxP^;Dnmt3b^loxP/loxP^*(control), *Dnmt1^loxP/loxP^;Villin-CreERT2* (Dnmt1 mutants) and *Dnmt1^loxP/loxP^;Dnmt3b^loxP/loxP^;Villin-CreERT2* (Dnmt1;Dnmt3b mutant) intestines were harvested one week following tamoxifen treatment for DNA methylation analysis. Crypts were isolated from paraffin-embedded tissue by laser capture microdissection, and the methylation levels of *LINE1* loci were determined by targeted bisulfite sequencing. LINE1 methylation is significantly decreased in both Dnmt1 and Dnmt1;Dnmt3b mutants compared (n=4--6 per genotype). Error bars are S.E.M. \*\*p\<0.01, one-way ANOVA. For data and *p*-values per CpG, refer to [Figure 5---source data 1](#SD6-data){ref-type="supplementary-material"}. (**B--C**) Hematoxylin and eosin staining of Dnmt1;Dnmt3b mutants (**C**) compared to controls (**B**). Double mutants display severe crypt and villus loss compared to controls. (**D**-**G**) Immunostaining confirms Dnmt1 and Dnmt3b protein loss in the Dnmt1;Dnmt3b mutant intestinal epithelium (**E**,**G**) compared to control (**D**,**F**). (**H**,**I**) Immunofluorescent staining for Ki67 (red), which marks proliferating cells, and γH2AX (green), which marks DNA double-strand break loci as a marker of genome instability. One week following tamoxifen injection, Dnmt1;Dnmt3b mutants (I) display decreased proliferation and increased DNA damage compared to controls (**H**). (**J**,**K**) Immunofluorescent TUNEL staining (red), which marks apoptotic nuclei, and E-cadherin (green), to outline the intestinal epithelium. One week after tamoxifen treatment, Dnmt1;Dnmt3b mutants (**K**) display increased crypt cell apoptosis relative to controls (**J**). All scale bars are 50 μm. For all staining, n=3 biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.015](10.7554/eLife.12975.015)10.7554/eLife.12975.016Figure 5---source data 1.Contains targeted bisulfite sequencing data shown in [Figure 5A](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.016](10.7554/eLife.12975.016)10.7554/eLife.12975.017Figure 5---source data 2.Contains targeted bisulfite sequencing data presented in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.017](10.7554/eLife.12975.017)10.7554/eLife.12975.018Figure 5---source data 3.Contains targeted bisulfite sequencing data shown in [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.018](10.7554/eLife.12975.018)10.7554/eLife.12975.019Figure 5---figure supplement 1.Ablation of *Dnmt3b* and *Dnmt1* induces genome demethylation at *H19* loci.(**A**) *Dnmt1^loxP/loxP^;Dnmt3b^loxP/loxP^*(control), and *Dnmt1^loxP/loxP^;Dnmt3b^loxP/loxP^;Villin-CreERT2* (Dnmt1;Dnmt3b mutant) intestines were harvested one week following tamoxifen treatment for DNA methylation analysis. Crypts were isolated from paraffin-embedded tissue by laser capture microdissection, and the methylation levels of the *H19* imprinting control region was determined by targeted bisulfite sequencing. *H19* methylation is significantly decreased in the Dnmt1;Dnmt3b mutants, relative to controls, when comparing averages of the entire sequenced region (n=4--6 per genotype). Error bars are S.E.M. \*p\<0.05, Student's *t*-test. For data and *p*-values per each CpG, refer to [Figure 5---source data 2](#SD7-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.019](10.7554/eLife.12975.019)10.7554/eLife.12975.020Figure 5---figure supplement 2.*Dnmt3b* deletion has no effect on epithelial proliferation, genome stability, or cell death within one week.(**A**,**B**) *Dnmt1^loxP/loxP^; Dnmt3b^loxP/loxP^* (**A**, control) and *Dnmt1^loxP/+^;Dnmt3b^loxP/loxP^;Villin-CreERT2* (**B**, Dnmt3b mutant) intestinal epithelium one week after tamoxifen injection. Hematoxylin and Eosin staining demonstrates no difference in epithelial integrity in the Dnmt3b mutant (**B**) versus control (**A**). (**C**,**D**) Immunofluoresence for Dnmt3b confirms loss of protein in tamoxifen-treated Dnmt3b mutant (**D**) compared to control (**C**). (**E**,**F**) Co-staining for Ki67 (red), a marker of proliferation, and γH2AX (green), which marks DNA double-stranded breaks. Both control (**E**) and Dnmt3b-deficient (**F**) epithelia have minimal γH2AX foci and display no difference in proliferation. (**G**,**H**) TUNEL staining to detect apoptosis (red) with E-cadherin (green) to outline the epithelium. No apoptotic nuclei is found in control (**G**) or Dnmt3b mutant (**H**) crypt cells. All scale bars are 50 μm. For all staining, n=3 biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.020](10.7554/eLife.12975.020)10.7554/eLife.12975.021Figure 5---figure supplement 3.Ablation of *Dnmt3b* alone is not sufficient to induce genome demethylation.Intestines from *Dnmt3b^loxP/loxP^*(control, n=4) and *Dnmt3b^loxP/loxP^Villin-CreERT2* (Dnmt3b mutant, n=2) mice were harvested one week after tamoxifen treatment. Crypt cells were isolated by laser capture microdissection and the methylation levels of *LINE1* loci and the imprinting control region of *H19* were determined by targeted bisulfite sequencing. (**A**,**B**) Methylation of LINE1 (**A**) and *H19* (**B**) are similar in Dnmt3b mutants compared to controls. In all graphs, error bars are S.E.M. For data and *p*-values per CpG, refer to [Figure 5---source data 3](#SD8-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.021](10.7554/eLife.12975.021)

Histological examination revealed a grossly abnormal epithelium in *Dnmt1;Dnmt3b* mutantmice, with many areas lacking villi and/or crypts completely ([Figure 5B--C](#fig5){ref-type="fig"}). We performed immunohistochemistry for Dnmt1 and Dnmt3b to confirm loss of both proteins in the majority of the epithelium ([Figure 5D--G](#fig5){ref-type="fig"}). Differentiation in the double mutant intestine was largely unaffected, and exhibited normal distribution of goblet cells, Paneth cells, and enterocytes (data not shown). Unlike the situation in Dnmt1 mutants, many crypts in double Dnmt1;Dnmt3b mutants were completely Ki67-negative, and harbored extensive DNA damage as indicated by γH2AX foci ([Figure 5H--I](#fig5){ref-type="fig"}). TUNEL staining revealed increased crypt cell apoptosis in *Dnmt1;Dnmt3b* mutants compared to sibling controls ([Figure 5J--K](#fig5){ref-type="fig"}). Overall, the *Dnmt1;Dnmt3b* double mutants displayed increased phenotypic severity compared to *Dnmt1* single mutants, characterized by hypomethylation, DNA damage, and cell death.

To confirm that *Dnmt3b* ablation alone does not replicate the *Dnmt1;Dnmt3b* double mutant phenotype, we also analyzed the intestine of *Dnmt1^loxP/+^;Dnmt3b^loxP/loxP^;Villin-CreERT2 (Dnmt3b* mutant) mice. Dnmt3b deletion was confirmed by immunoflourescent staining, and we proceeded to further histological analysis ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Loss of Dnmt3b had no affect on intestinal crypt-villus architecture ([Figure 5---figure supplement 2A--B](#fig5s2){ref-type="fig"}), and immunostaining for cell proliferation, DNA damage, and apoptosis was similar to controls ([Figure 5---figure supplement 2E--H](#fig5s2){ref-type="fig"}). Furthermore, methylation of both the LINE1 repetitive loci and the *H19* imprinting control region in Dnmt3b mutant crypt cells was equivalent to controls ([Figure 5---figure supplement 3A--B](#fig5s3){ref-type="fig"}). These results demonstrate that Dnmt3b alone is not required for intestinal homeostasis.

Discussion {#s3}
==========

DNA methylation has been linked to genomic instability in multiple contexts, in both cell lines and in disease. *Dnmt1* hypomorphic mice exhibit increased chromosomal duplications and rearrangements, and develop invasive T-cell lymphomas at approximately four months of age ([@bib13]). It is important to note that these effects are not restricted to Dnmt1 deficiency. Loss of *Dnmt3b* also induces hypomethylation and chromosomal instability in mouse embryonic fibroblasts ([@bib8]), suggesting that both Dnmt1 and Dnmt3b are crucial for maintaining DNA methylation and preserving genome integrity.

In some cases, de novo methyltransferases are essential for methylation of certain elements or enhancers, and cannot be compensated for by Dnmt1. For example, hematopoietic stem cells (HSCs) require Dnmt3a for normal self-renewal and differentiation processes ([@bib3]). Loss of Dnmt3a in HSCs causes demethylation at essential stem cell genes, inducing hyper-proliferation and reducing differentiation rates ([@bib3]). Dnmt3b also contributes to silencing of germline genes in somatic cells ([@bib37]), and maintenance methylation in ES cells ([@bib6]; [@bib26]). Our work adds to this body of evidence that implicates a crucial role for DNA methylation in maintaining genome stability. Given that methylation of LINE elements is significantly reduced, it is tempting to speculate that reactivation of retrotransposition might be a contributing factor to genome instability.

Aberrant DNA methylation and genome instability correlate in a number of gastrointestinal pathologies, including inflammatory bowl disease (IBD) and colitis-associated cancer ([@bib16]). The phenotype presented in our *Dnmt1;Dnmt3b* double mutant mice is reminiscent of mouse models of IBD, in which altered epithelial barrier function leads to increased immune cell recruitment and chronic inflammation in the gastrointestinal tract ([@bib39]). Indeed, a recent study in zebrafish demonstrated that loss of DNA methylation at the tumor necrosis factor alpha (*tnf-a*) promoter prompted increased *tnf-a* expression in the gut epithelium, leading to elevated apoptosis, barrier dysfunction, and immune cell localization ([@bib29]). In a chemically induced mouse model of IBD, inhibition of DNA methylation aggravated the inflammatory response, suggesting DNA methylation acts to protect against inflammation and IBD ([@bib21]). Our data support the hypothesis that DNA methylation supports intestinal epithelial homeostasis and helps to maintain crypt architecture.

Current dogma holds that deletion of Dnmt1 is lethal in all dividing somatic cells ([@bib27]); conversely, we find that the rapidly dividing intestinal epithelium can survive without Dnmt1. Following acute loss of *Dnmt1, Dnmt3b* expression is induced, and methylation of repetitive elements is restored. However, if *Dnmt3b* is ablated concurrently with *Dnmt1,* restoration of DNA methylation is prevented, resulting in massive DNA damage, and cell death. It is important to note that our data does not provide direct evidence for methyltransferase activity of Dnmt3b at hemimethylated CpG sites, which are targeted by Dnmt1. Indeed, it is also possible that Dnmt3b is compensating for the loss of Dnmt1 via repeated cycles of de novo methylation, in which Dnmt3b remethylates regions that are demethylated following Dnmt1 deletion after each cycle of DNA replication.

Interestingly, we find that Dnmt3a cannot compensate adequately for the loss of both Dnmt1 and Dnmt3b, nor is Dnmt3a required in the absence of Dnmt1. Indeed, we see that the pressure to maintain Dnmt1 and/or Dnmt3b expression is so high that Dnmt3b^+^ escaper cells proliferate in excess to recover the intestinal epithelium in a small subset of mutants ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Although the basal levels of Dnmt3a mRNA in the control intestinal epithelium are much higher than those of Dnmt3b or Dnmt1 ([Figure 3A](#fig3){ref-type="fig"}), Dnmt3a does not appear to be necessary to maintain intestinal homeostasis or DNA methylation patterns. This may be due to a number of factors, such as differing abilities of the methyltransferases to interact with cofactors and epigenetic complexes. Both Dnmt1 and Dnmt3b interact with the polycomb group repression complexes (PRC1 and PRC2), and regulate distinct sites in colorectal cancer development ([@bib19]). Furthermore, different methyltransferases are required in distinct ways in certain tissue and cell types. For example, in the hematopoietic system, loss of Dnmt3a leads to elevated proliferation rates and cancer development, while loss of Dnmt3b has little to no effect on hematopoietic stem cell function ([@bib3]; [@bib4]).

In conclusion, we show that Dnmt1 and Dnmt3b cooperate to maintain methylation in the adult mouse intestinal epithelium. Loss of Dnmt1 results in short-term hypomethylation, genomic instability, and apoptosis, followed by recovery over time. Dnmt3b is upregulated in response to deletion of *Dnmt1* in the adult intestine, and is required to recover DNA methylation and epithelial integrity. These results provide the first example of a rapidly dividing somatic tissue that can survive in the absence of Dnmt1, and suggest that the strict division of the Dnmt enzymes into 'de novo' and 'maintenance' methyltransferases might not fully represent the situation in vivo.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

*Dnmt1*^loxP/loxP^ and *Dnmt3b*^loxP/loxP^ mice were provided by Rudolf Jaenisch ([@bib18]; [@bib28]). *Dnmt3a^loxP/loxP ^*mice were provided by En Li ([@bib20]), and *Villin-CreERT2* mice were received from Sylvie Robine ([@bib9]). For *Dnmt1* and *Dnmt3b* deletion experiments, Cre-recombination was induced by three daily intraperitoneal injections of 1.6 mg tamoxifen (Sigma-Aldrich, St. Louis, MO) in an ethanol/sunflower oil mixture. In all experiments, littermate controls without the *Villin-CreERT2* transgene were also tamoxifen treated. All procedures involving mice were conducted in accordance with approved Institutional Animal Care and Use Committee protocols.

Histology {#s4-2}
---------

Tissues were isolated and fixed using 4% paraformaldehyde in PBS and then embedded in paraffin. Antigen retrieval was performed using the 2100 Antigen-Retriever in Buffer A (Electron Microscopy Sciences, Hatfield, PA) and standard immunostaining procedures were performed for Dnmt1 (Santa Cruz), Dnmt3a (Santa Cruz Biotechnology, Dallas, TX), Dnmt3b (Imgenex, San Diego, CA), E-Cadherin (BD Biosciences, San Jose, CA), Ki67 (BD Biosciences), and γH2AX (Cell Signaling Technology, Berverly, MA). TUNEL staining was performed using TUNEL Label and Enzyme (Roche, Indianapolis, IN) and AlexaFluor 555-aha-dUTP (Molecular Probes, Eugene, OR). All microscopy was performed on a Nikon Eclipse 80i (Tokyo, Japan). For all immunofluorescence and immunohistochemistry staining, n=3 biological replicates per genotype, per timepoint.

Laser capture microdissection {#s4-3}
-----------------------------

Crypt cell DNA was collected using a Leica LMD7000 Laser Microdissection microscope (Wetzlar, Germany) and the Arcturus PicoPure DNA isolation kit (Applied Biosystems, Carlsbad, CA).

qRT-PCR {#s4-4}
-------

Intestines were gently scraped to remove villi, and treated with EDTA to isolate crypt cells. RNA was extracted using the Trizol RNA isolation protocol (Invitrogen, Carlsbad, CA), followed by RNA cleanup using the RNeasy Mini Kit (Qiagen, Hilden, Germany). mRNA expression was determined using quantitative RT-PCR, as described previously ([@bib15]). The SYBR green qPCR master mix (Agilent, Santa Clara, CA) was used in all qPCR reactions, and the fold change was calculated relative to the geometric mean of *Tbp* and *β-Actin*, using the △CT method. The method of normalizing to the geometric mean of a set of reference genes has been described previously ([@bib36]). Primer sets can be found in [Table 1](#tbl1){ref-type="table"}.10.7554/eLife.12975.022Table 1.qRT-PCR primer sequences.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.022](10.7554/eLife.12975.022)GeneForward 5\'-3\'Reverse 5\'-3\'*Beta-actin*GAAGTGTGACGTTGACATCCGGTCAGCAATGCCTGGGTACAT*TBP*CCCCTTGTACCCTTCACCAATGAAGCTGCGGTACAATTCCAG*Dnmt1*CTTCACCTAGTTCCGTGGCTACCCTCTTCCGACTCTTCCTT*Dnmt3a*GCACCAGGGAAAGATCATGTCAATGGAGAGGTCATTGCAG*Dnmt3b*GGATGTTCGAGAATGTTGTGGGTGAGCAGCAGACACCTTGA

Targeted bisulfite sequencing {#s4-5}
-----------------------------

100 ng of mouse genomic DNA was bisulfite converted using the Epitect bisulfite kit (Qiagen). Template DNA was amplified using KAPA HIFI Uracel+ (KAPA Biosystems, Wilmington, MA) with primers directed to the LINE1 and H19 regions ([Table 2](#tbl2){ref-type="table"}). Sequencing libraries were prepared and analyzed using the BiSPCR^2^ strategy, described previously ([@bib1]).10.7554/eLife.12975.023Table 2.Bisulfite sequencing primer sets.**DOI:** [http://dx.doi.org/10.7554/eLife.12975.023](10.7554/eLife.12975.023)**GeneSequence (5\'-3\')**H19 PCR\#1 ForwardACACTCTTTCCCTACACGACGCTCTTCCGATCTGTTTGTTGAATTAGTTGTGGGGTTTATAH19 PCR\#1 ReverseGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTAAAAAAAAAAACTCAATCAATTACAATCCLINE1 PCR\#1 ForwardACACTCTTTCCCTACACGACGCTCTTCCGATCTGTTAGAGAATTTGATAGTTTTTGGAATAGGLINE1 PCR\#1 ReverseGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCCAAAACAAAACCTTTCTCAAACACTATATUnique Barcode PCR\#2 ForwardAATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACUnique Barcode PCR\#2 ReverseCAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTTCAGACGTGT[^3]

Statistical analysis {#s4-6}
--------------------

Where indicated, GraphPad Prism 6 (La Jolla, CA) was employed to calculate log-rank test and ANOVA statistics.
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Thank you for resubmitting your work entitled \"The \'de novo\' DNA methyltransferase *Dnmt3b* compensates the *Dnmt1*-deficient intestinal epithelium\" for further consideration at *eLife*. Your manuscript has been favorably evaluated by Janet Rossant (Senior editor), a Reviewing editor, and two reviewers.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Reviewer \#1:

In this manuscript by Eliott et al., the authors report their analysis on the important cooperation of *Dnmt1* and *Dnmt3b* in the maintenance of intestinal epithelial cell homeostasis. Their experiments led to the demonstration of the dramatic rescue, by *Dnmt3b*, of the phenotypes, hypomethylation and genomic instability caused by the loss of *Dnmt1* in the intestinal epithelium. In general, this is a very interesting and well-written manuscript. The results are clearly presented and provide important new information to this particular field. All experiments shown here support the conclusion drawn by the authors.

Reviewer \#2:

In the manuscript entitled \"The \'de novo\' DNA methyltransferase *Dnmt3b* compensates the *Dnmt1*-deficient intestinal epithelium\", Elliott et al. examine the role of DNA methylation in mammalian epithelial homeostasis by investigating the effect of *Dnmt1, Dnmt3a* and *Dnmt3b* knockout in murine intestine. Using appropriate genetic methods, they proved that *Dnmt3b*, but not *Dnmt3a*, can replace or at least compensate for *Dnmt1* to keep the integrity of the gut epithelia. Thus, this manuscript presents solid genetic evidence that these enzymes are functionally redundant in the gut epithelium. Considering the popular dogmatic view that Dnmt enzymes can be divided into two classes: \'de novo\' and \'maintenance\' methyltransferases, this novel finding is very important and I therefore recommend its publication in *eLife*. There are few additional points that the authors may discuss further:

1\) It seems appropriate to specify the region where the authors have observed global hypomethylation at the end of the subsection "*Dnmt1* ablation results causes weight loss, hypomethylation, and genomic instability "by adding \'in LINE1 repeats and H19 imprinting region\'.

2\) *Dnmt3a* and *Dnmt3b* are closely related methyltransferases both in sequence homology and domain architecture. It is therefore very interesting that *Dnmt3a* couldn\'t compensate the loss of *Dnmt1* even though the basal level of *Dnmt3a* is higher than that of *Dnmt3b*. The authors may discuss this interesting point in the Discussion.

3\) *Dnmt1;Dnmt3b* compound mutants showed severe phenotype and more than 50% lethality. However, after two weeks, the phenotype of these animals stabilized with regards to both survival rate and weight loss. Does this mean that there are additional methyltransferases that can further compensate for the loss of the two enzymes? Do the authors have any idea which methyltranserases could be involved in this compensatory mechanism? Can the authors perform for example qPCR analysis to further investigate this?

4\) The number of goblet cells seems to be altered in the *Dnmt1;Dnmt3b* compound mutant intestine. It is recommended to provide higher magnification images of H&E and staining for markers of goblet cells (Alcian blue), Paneth cells (Lysozyme), enteroendocrine cell (Chromogranin) and intestinal stem cells (Olfm4/Lgr5). Together this data will provide basic information of the phenotype of this precious compound mutant mouse.
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Author response

Reviewer \#2: In the manuscript entitled \"The \'de novo\' DNA methyltransferase Dnmt3b compensates the Dnmt1-deficient intestinal epithelium\", Elliott et al. examine the role of DNA methylation in mammalian epithelial homeostasis by investigating the effect of Dnmt1, Dnmt3a and Dnmt3b knockout in murine intestine. Using appropriate genetic methods, they proved that Dnmt3b, but not Dnmt3a, can replace or at least compensate for Dnmt1 to keep the integrity of the gut epithelia. Thus, this manuscript presents solid genetic evidence that these enzymes are functionally redundant in the gut epithelium. Considering the popular dogmatic view that Dnmt enzymes can be divided into two classes: \'de novo\' and \'maintenance\' methyltransferases, this novel finding is very important and I therefore recommend its publication in eLife. There are few additional points that the authors may discuss further: 1) It seems appropriate to specify the region where the authors have observed global hypomethylation at the end of the subsection "Dnmt1 ablation results causes weight loss, hypomethylation, and genomic instability "by adding \'in LINE1 repeats and H19 imprinting region\'.

We altered the text, to read "Overall, these results suggest a phenotype in which loss of *Dnmt1* results in hypomethylation of LINE1 repeats and the H19 imprinting control region, increased DNA damage, and apoptosis."

*2) Dnmt3a and Dnmt3b are closely related methyltransferases both in sequence homology and domain architecture. It is therefore very interesting that Dnmt3a couldn\'t compensate the loss of Dnmt1 even though the basal level of Dnmt3a is higher than that of Dnmt3b. The authors may discuss this interesting point in the Discussion.*

Thank you for this helpful suggestion. We added a new paragraph to the Discussion to review the different functions of de novo methyltransferases, and to examine why *Dnmt3a* cannot compensate for *Dnmt1* and *Dnmt3b* loss.

3\) Dnmt1;Dnmt3b compound mutants showed severe phenotype and more than 50% lethality. However, after two weeks, the phenotype of these animals stabilized with regards to both survival rate and weight loss. Does this mean that there are additional methyltransferases that can further compensate for the loss of the two enzymes? Do the authors have any idea which methyltranserases could be involved in this compensatory mechanism? Can the authors perform for example qPCR analysis to further investigate this?

Reviewer \#2was concerned about *Dnmt1;Dnmt3b* double mutants that were able to survive, and wanted us to provide evidence of a compensatory mechanism. Thank you for this comment, as we believe answering this question in more detail adds to the quality of our manuscript. As mentioned in the text, we believe that *Dnmt3b*-positive cells, which escape Cre-loxP recombination, proliferate and repopulate the intestinal epithelium. We have provided a new figure, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, which shows an example of a *Dnmt3b*-positive escaper crypt in the double mutant small intestine. We show that this escaper crypt does not display the DNA damage phenotype present in mutant crypts by co-staining for *Dnmt3b* and γH2AX. γH2AX is only present in the mutant crypts, and is not present in the *Dnmt3b*-positive escaper crypts.

*4) The number of goblet cells seems to be altered in the Dnmt1;Dnmt3b compound mutant intestine. It is recommended to provide higher magnification images of H&E and staining for markers of goblet cells (Alcian blue), Paneth cells (Lysozyme), enteroendocrine cell (Chromogranin) and intestinal stem cells (Olfm4/Lgr5). Together this data will provide basic information of the phenotype of this precious compound mutant mouse.*

Reviewer \#2'sfinal concern was that we should provide further characterization of the differentiation of the double mutant intestinal epithelium. He suggested staining for goblet cells, Paneth cells, enterocytes, and Olfm4 and Lgr5 to mark intestinal stem cells. This amount of staining, in multiple biological replicates, would take several months to complete, and would probably not yield data to further the main point of our manuscript. Furthermore, Olfm4 and Lgr5 would require sensitive in situ hybridization, because antibodies are not readily available. We have preliminary evidence to suggest that differentiation (goblet cells, Paneth cells, enterocytes) is largely unaffected in these double mutants, which we have indicated in the text.

[^1]: The Jackson Laboratory for Genomic Medicine, Farmington, United States.

[^2]: These authors contributed equally to this work.

[^3]: Red text, Illumina adapter sequence; blue text, Unique Illumina Sequencing Barcodes, 1--48.
